Difference between revisions of "Dacarbazine (DTIC)"
Jump to navigation
Jump to search
m |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Hodgkin lymphoma]] | ||
| + | *[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | ||
| + | *[[Melanoma]] | ||
| + | *[[Neuroendocrine tumors]] | ||
| + | *[[Sarcoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/chemotherapy/drug-info/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 5/27/1975: Initial FDA approval | ||
==Also known as== | ==Also known as== | ||
| Line 28: | Line 38: | ||
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
[[Category:Sarcoma medications]] | [[Category:Sarcoma medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1975]] | ||
Revision as of 17:18, 3 November 2014
General information
Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Melanoma
- Neuroendocrine tumors
- Sarcoma
Patient drug information
- Dacarbazine (DTIC) patient drug information (Chemocare)[3]
- Dacarbazine (DTIC) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 5/27/1975: Initial FDA approval
Also known as
DIC, DTIC-Dome, Imidazole carboxamide